Media stories about Aptevo Therapeutics (NASDAQ:APVO) have trended positive this week, Accern reports. The research firm identifies positive and negative press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Aptevo Therapeutics earned a media sentiment score of 0.25 on Accern’s scale. Accern also gave headlines about the biotechnology company an impact score of 46.5479892445927 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the next several days.
Several equities research analysts have recently commented on APVO shares. ValuEngine cut Aptevo Therapeutics from a “buy” rating to a “hold” rating in a research note on Monday, July 30th. Zacks Investment Research cut Aptevo Therapeutics from a “hold” rating to a “sell” rating in a research note on Tuesday, July 10th. Finally, Piper Jaffray Companies restated an “overweight” rating and set a $11.00 price target on shares of Aptevo Therapeutics in a research note on Friday, August 10th.
Shares of Aptevo Therapeutics stock traded down $0.23 during trading hours on Friday, hitting $5.40. 66,300 shares of the company were exchanged, compared to its average volume of 170,502. Aptevo Therapeutics has a 1 year low of $1.15 and a 1 year high of $6.35. The company has a debt-to-equity ratio of 0.20, a current ratio of 4.47 and a quick ratio of 4.39. The stock has a market capitalization of $109.49 million, a PE ratio of -3.53 and a beta of 0.21.
About Aptevo Therapeutics
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Featured Article: Should you buy a closed-end mutual fund?
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.